There is clear evidence that BCG protects against leprosy, but cross-immunity with environmental mycobacteria can interfere with vaccination protection. Some have cast doubts whether BCG vaccination can offer a significant impact against leprosy in the Brazilian Amazon, which is an endemic area for leprosy and with a high prevalence of environmental mycobacteria. This study was designed to esti...

12 Affiliations: 13 14 Vandana Singh 15 Senior Project Fellow 16 Division of Microbiology 17 CSIR-Central Drug research Institute 18 Lucknow, 226031, INDIA, E. mail: [email protected] 19 20 Rajesh Kumar Biswas 21 Senior Research Fellow 22 Division of Microbiology 23 CSIR-Central Drug research Institute 24 Lucknow, 226031, INDIA, E. mail: [email protected] 25 26 27 28 29 Corresponden...

Background: Bacillus Calmette-Guérin (BCG) vaccination is recommended for newborn infants worldwide to prevent tuberculosis. However, complications do occur inevitably in a very low rate, among which the most serious is disseminated disease. The disseminated bacillus Calmette–Guérin disease is a rare disease with high fatality, and can be seen among persons with an underlying immunodeficiency. ...

Non-muscle-invasive bladder cancer is a frequent and heterogeneous disease with varying oncologic outcomes. The main goal in treating is to prevent recurrences and progression to muscle-invasive disease. Developments to improve the quality of transurethral resection of the bladder tumor and new chemotherapeutic options, including two device-assisted therapies, are being discussed. A problem is ...

Recibido: 08/08/2009 Aceptado: 02/10/2009 Introduction Short title: Bacillus Calmette-Guérin disease after intravesical instillation Two exemplary case reports of respiratory granulomatous infection caused by bacillus of Calmette-Guérin (BCG) in patients who were repeatedly treated with local, intravesical adjuvant BCG therapy for a relapsing transitional bladder carcinoma, are outlined and dis...

Bladder cancer is an important health problem worldwide due to high prevalence rates and costs related to treatment. A reduction in recurrence rates has been observed since the introduction of adjuvant intravesical immunotherapy with bacillus Calmette-Guerin. There are mild complications that are easily solved by local measures and orientations. Bladder contracture, a rare and severe local comp...

The influence of mineral oil content on the antitumor activity of emulsified Bacillus Calmette-Guérin cell walls (CW) was studied in mice each with an established transplant of a syngeneic fibrosarcoma. Animals received intratumoral injections of CW (0.02 to 0.6 mg/mouse) emulsified in 1 to 9% oil. The number of animals in which tumor regressed completely depended on the concentration of oil in...

Intravesical immunotherapy with attenuated strains of Mycobacterium bovis is a widely used therapeutic option in patients with non-muscle-invasive transitional cell carcinoma of the bladder. A rare complication of intravesical therapy with the Bacillus Calmette-Guérin vaccine is granulomatous prostatitis, which due to increasing levels of prostate-specific antigen and abnormalities found in tra...

Intravesical instillation of Bacillus Calmette-Guerin (BCG) hasbecome an established adjuvant treatment for superficial bladdercarcinoma. This treatment is associated with a relatively high rateof side effects which are mostly reversible spontaneously or canbe treated symptomatically. Serious systemic side effects are lessfrequent. One of rare complications is gran...

Intravesical instillation of Bacillus Calmette-Guérin is currently used as adjuvant therapy for superficial, non-muscle invasive bladder cancer (NMIBC). However, nearly 40% of patients with NMIBC will fail Bacillus Calmette-Guérin therapy. In an attempt to investigate the feasibility of using insect baculovirus-based vectors for bladder cancer therapy, we observed that intravesical instillation...